Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Sauter, Edward R ^a   Qin, Wenyi ^a   Hewett, John E ^b   Ruhlen, Rachel L ^a   Flynn, John T ^c   Rottinghaus, George ^d   Chen, Yin Chieh ^d  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; RALOXIFENE; TAMOXIFEN; VINCRISTINE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; CATARACT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOWN REGULATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG WITHDRAWAL; EDEMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; HEART PALPITATION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LOW DRUG DOSE; MULTICENTER STUDY; MUSCLE TIGHTNESS; NAUSEA; NEPHROTOXICITY; POSTMENOPAUSE; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; SWEATING; TASTE DISORDER; URINARY URGENCY; VAGINA DISCHARGE; BODY FLUID; BREAST TUMOR; CANCER INVASION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; LABORATORY DIAGNOSIS; MENOPAUSE; METABOLISM; METHODOLOGY; MIDDLE AGED; NIPPLE; OSMOLARITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SUCTION;

ADULT; AGED; AGED, 80 AND OVER; BODY FLUIDS; BREAST NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NIPPLES; OSMOLAR CONCENTRATION; PROGNOSIS; PYRAZOLES; RISK FACTORS; SPECIMEN HANDLING; SUCTION; SULFONAMIDES;

EID: 40349093194     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-49     Document Type: Article

References (19)

1. Whittle BJ Gastrointestinal effects of nonsteroidal anti-inflammatory drugs Fundam Clin Pharmacol 2003, 17(3):301-313 10.1046/ j.1472-8206.2003.00135.x 12803569
2. Masferrer JL Leahy KM Koki AT Zweifel BS Settle SL Woerner BM Edwards DA Flickinger AG Moore RJ Seibert K Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 2000, 60(5):1306-1311 10728691
3. Taketo MM Cyclooxygenase-2 inhibitors in tumorigenesis (Part II) J Natl Cancer Inst 1998, 90(21):1609-1620 10.1093/jnci/90.21.1609 9811310
4. Fulton AM Gimotty P Alonsozana E Dorsey R Kundu N Elevated prostaglandin E2 (PGE2) levels in human breast cancer are associated with poor long-term survival. Proc Am Assn Cancer Res 2000, 41:3660A
5. Meagher EA Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: Clinical implications Drug Saf 2003, 26(13):913-924 10.2165/00002018-200326130-00001 14583067
6. Abou-Issa HM Alshafie GA Seibert K Koki AT Masferrer JL Harris RE Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis Anticancer Res 2001, 21(5):3425-3432 11848504
7. Alshafie G Abou-Issa HM Seibert K Harris RE Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in a rat mammary tumor model. Oncol Rep 2000, 7(6):1377-81 11032948
8. Harris RE Beebe-Donk J Alshafie GA Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors BMC Cancer 2006, 6:27 1373658 16445867 10.1186/1471-2407-6-27
9. Lanza-Jacoby S Miller S Flynn J Gallatig K Daskalakis C Masferrer JL Zweifel BS Sembhi H Russo IH The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice Cancer Epidemiol Biomarkers Prev 2003, 12(12):1486-1491 14693742
10. Cervi D Klement G Stempak D Baruchel S Koki A Ben-David Y Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease Clin Cancer Res 2005, 11(2 Pt 1):712-719 15701860
11. Williams CS Watson AJ Sheng H Helou R Shao J DuBois RN Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models Cancer Res 2000, 60(21):6045-6051 11085526
12. Hale TW McDonald R Boger J Transfer of celecoxib into human milk J Hum Lact 2004, 20(4):397-403 10.1177/0890334404269875 15479658
13. Chow HH Anavy N Salazar D Frank DH Alberts DS Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography J Pharm Biomed Anal 2004, 34(1):167-174 10.1016/ j.japna.2003.08.018 14738931
14. Sauter ER Ross E Daly M Klein-Szanto A Engstrom PF Sorling A Malick J Ehya H Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk Br J Cancer 1997, 76(4):494-501 9275027
15. Sauter ER Schlatter L Hewett J Koivunen D Flynn JT Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer Cancer Epidemiol Biomarkers Prev 2004, 13(11 Pt 1):1745-1750 15533902
16. Sauter ER Qin W Schlatter L Hewett JE Flynn JT Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer BMC Cancer 2006, 6:248 1621075 17049084 10.1186/1471-2407-6-248
17. Sauter ER Daly M Linahan K Ehya H Engstrom PF Bonney G Ross EA Yu H Diamandis E Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk Cancer Epidemiol Biomarkers Prev 1996, 5(12):967-970 8959318
18. Schonberger F Heinkele G Murdter TE Brenner S Klotz U Hofmann U Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection J Chromatogr B Analyt Technol Biomed Life Sci 2002, 768(2):255-260 10.1016/ S1570-0232(01)00588-8 11888053
19. Brenner SS Herrlinger C Dilger K Murdter TE Hofmann U Marx C Klotz U Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib Clin Pharmacokinet 2003, 42(3):283-292 10.2165/00003088-200342030-00003 12603175